Texas TX
Biogen to bulk up rare disease treatments with $7 billion Reata acquisition
Alzheimer's treatment developer Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The drugmaker said Friday it will pay…
